Hepatitis Market
Hepatitis
is the inflammation of the liver. The condition can be limited to self or can
advance to scarring, cirrhosis or liver cancer. Hepatitis viruses are the most
common origin of hepatitis in all over the world. Sometimes, other infections,
toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can
also cause hepatitis.
There
are five main hepatitis viruses, like types A, B, C, D and E. These five types
are of the most significant concern. In particular, types B and C cause chronic
disease in millions of people and are the cause of liver cirrhosis and cancer.
Hepatitis
A and E are characteristically caused due to contaminated food and water
ingestion. Hepatitis B, C and D usually occur because of the result of
parenteral contact with infected body fluids. Acute infection may arise with no
or limited symptoms or may involve symptoms such as jaundice (yellowing of the
skin and eyes), dark-coloured urine, extreme fatigue, nausea, barfing and feel
abdominal pain.
One
of the viruses is the Hepatitis B Virus (HBV) that causes Hepatitis B, which is
a life-threatening liver infection. It is a significant concern and a
significant global health problem. It can be an acute infection or a chronic
infection. Chronic Hepatitis B Virus infection is the main cause of chronic
hepatitis and advanced-stage liver diseases, including cirrhosis and
hepatocellular carcinoma (HCC). Hepatitis B virus is a blood-borne and
sexually-transmitted virus, which is acquired by percutaneous and mucosal
exposure to blood or/ and body fluids of an infected person. The clinical
manifestations of hepatitis from different origins may be quite similar.
Hepatitis
B Virus Infection is estimated to have 786,000 deaths and the vast majority
being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000
deaths). Hepatitis B Virus infection ranks 15th among all causes of human
mortality. Around two billion people worldwide have been infected with the
Hepatitis B Virus infection and about 360 million live with chronic Hepatitis B
infection. The Hepatitis B Virus prevalence in the general population is
heterogeneous in Europe, ranging 0.1-7 % depending on the country. The
Hepatitis B Virus global prevalence varies widely. It ranges from 0.5 % in
areas of low endemicity (e.g., North America and some Western European
countries) to rates above 8% in the highly endemic countries of Sub- Saharan
Africa and East Asia.
Now
taking into consideration of Hepatitis B virus market, it is dominated by
chronic Hepatitis B medication, which focuses on viral suppression and includes
two therapy classes, oral nucleoside analogues (NUC) – Nucleoside/Nucleotide
Reverse Transcriptase Inhibitors (NRTIs) and pegylated interferon (PEG-IFN).
For acute hepatitis B infection, no specific treatment is available; only care
is focused on maintaining comfort and required nutritional balance, including
replacement of fluids (lost due to vomiting), etc.
Many
companies are developing drugs for Hepatitis B Virus market treatment.
DelveInsight is one such company that prepares market reports, pipeline
reports, and epidemiology reports. It proffers a detailed overview of the
Hepatitis B Virus market and an in-depth comprehension of the historical and
forecasted Hepatitis B Virus market epidemiology. It shows Hepatitis B Virus
market treatment patterns, potential upcoming drugs and also recognises the
best of the Hepatitis B Virus market opportunities by showing the current and
forecasted Hepatitis B Virus market revenue, sales trends, and drug uptake
during the study period from 2017-2028. The Hepatitis B Virus market report
also proffers in-depth analysis of the disease overview by including details
like disease definition, classification, symptoms, etiology, pathophysiology
and diagnostic trends. The exhaustive details about Hepatitis B Virus market
treatment algorithms and treatment guidelines in the United States, Europe, and
Japan are also provided in the report.
Comments
Post a Comment